Loading...

NMRA NEUMORA THERAPEUTICS INC Management Changes 8-K Filing

NMR

NMR

NEUMORA THERAPEUTICS INC

(NMRA)

2025 8-K

Financial Results Announcement

Investor Presentation

Investor Presentation

Positive Study Results

Stock Conversion Notice

Financial Results Update

Phase 1 Study Initiated

Positive Drug Data

Financial Statements

Delisting due to Non-Compli...

Financial Statements

Financial Results

Leadership Changes

Leadership Changes

Investor Presentation

Q3 Financial Results

External Links:

Neumora Therapeutics reported leadership changes on February 14, 2025, including a separation agreement with former CEO Henry Gosebruch and a new executive employment agreement with Paul L. Berns as CEO, detailing salary, bonuses, and stock options.

AI Assistant

NEUMORA THERAPEUTICS INC

2025

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.